Trending Up: FDA’s Drug GMP Data Integrity Warning Letters
This article was originally published in The Gold Sheet
See how the trend in FDA drug GMP warning letters has increased, both in terms of the number of warning letters and the number of countries where they went.
You may also be interested in...
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?